Review
Published · Updated · 1 min read
Oral terbinafine for dermatophytosis among MSM: a report from EADV 2026
What it means for practice
The congress report describes oral terbinafine for 8–12 weeks as first-line treatment for the reported dermatophytosis among men who have sex with men. The available excerpt provides no dose or efficacy data.
Summary
Clinical context
The available excerpt of a Le Quotidien du Médecin report from EADV 2026 describes dermatophytosis spreading through sexual transmission among men who have sex with men (MSM) in Europe. The infection presents with inflammatory, painful, erythematous, scaly plaques. According to the report, these are often located on the face or in the perianal or perigenital region.
What was reported about treatment
Dermatologist Alba Catala from Barcelona describes oral terbinafine for 8–12 weeks as first-line treatment for the reported infection. The available text provides no dose, patient numbers, clinical or mycological response rates, or adverse reaction data.
Limits of the available information
This is a congress news report, not a clinical study report or a clinical guideline. The remainder of the article is subscriber-only; the excerpt does not allow assessment of the evidence supporting this approach, comparative treatment efficacy, or criteria for selecting treatment duration. Source.
Source
-
Congrès EADV 2026 : les brèves de la dermatologie. Le Quotidien du Médecin.
Reviewed by: DrugCard editorial team ·
This article does not replace clinical judgement. Disclaimer
